Seaport Therapeutics (SPTX) Stock Overview

Operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. More details

SPTX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 70.2%

Risk Analysis

Earnings are forecast to decline by an average of 18.3% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

SPTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW496,749 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

496,749 investors already sharing narratives

View all narratives

Seaport Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Seaport Therapeutics
Historical stock prices
Current Share Price	US$20.57
52 Week High	US$23.00
52 Week Low	US$14.85
Beta	0
1 Month Change	25.12%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	3.68%

Recent updates

Shareholder Returns

	SPTX	US Pharmaceuticals	US Market
7D	-3.9%	1.4%	1.6%
1Y	n/a	48.6%	18.6%

Return vs Industry: Insufficient data to determine how SPTX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SPTX performed against the US Market.

Price Volatility

Is SPTX's price volatile compared to industry and market?
SPTX volatility
SPTX Average Weekly Movement	11.0%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: SPTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SPTX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2024	58	Daphne Zohar	www.seaporttx.com

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects.

Seaport Therapeutics, Inc. Fundamentals Summary

How do Seaport Therapeutics's earnings and revenue compare to its market cap?
SPTX fundamental statistics
Market cap	US$1.10b
Earnings (TTM)	-US$87.16m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-12.6x

P/E Ratio

Is SPTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPTX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$87.16m
Earnings	-US$87.16m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.63
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SPTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/05 05:55
End of Day Share Price	2026/07/02 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seaport Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yigal Nochomovitz	Citigroup Inc
Salveen Richter	Goldman Sachs
Tessa Romero	J.P. Morgan

Seaport Therapeutics, Inc.NasdaqGS:SPTX Stock Report